Tocilizumab for the treatment of COVID-19 in intensive care patients: effect on days free of ventilatory support.

QIMR Berghofer Medical Research Institute0 个研究点目标入组 150 人开始时间: 2020年5月19日最近更新: 2022年8月29日

试验速览

暂无简介。

•1.Male or female aged greater than or equal to 18 years
•2.Confirmed SARS-CoV-2 by PCR with sample taken within 14 days prior to randomisation
•3. Requirement for invasive or non-invasive ventilatory support or admission to ICU (or planned commencement of invasive or non-invasive ventilatory support, or planned admission to ICU)
•4. Enrolled prior to or within 24 hours of ICU admission

•1.Absolute neutrophil count less than 0.5x10e9/Litre, platelets less than 50x10e9/Litre
•2.Previous TNF alpha antagonist treatment within the last 3 months
•3.Confirmed bacterial sepsis or untreated bacterial, mycobacterial or fungal infection
•4.Untreated hepatitis B virus infection
•5.Recent major surgery within the last 8 weeks
•6.Organ transplant recipients
•7.Primary or secondary immunodeficiency
•8.History of diverticulitis, inflammatory bowel disease, or other symptomatic gastrointestinal condition that might predispose to bowel perforation
•9.Known cirrhosis or aminotransferases greater than 5 times upper limit of normal
•10.Pregnant or breastfeeding
•11.Known allergy or hypersensitivity to TCZ or other monoclonal antibodies
•12.Previous participation in the trial
•13.Patient being treated with palliative intent, or not expected to be alive in 48 hours

发起方